| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1K | 3.92M | 10.17M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -1K | -3.92M | -10.17M | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -3920% | -1.59% | 1% | - | - | - |
| Operating Expenses | 8.22M | 141.15M | 150.95M | 356.91M | 272.56M | 293.14M | 272.72M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.21M | 21.78M | 28.27M | 50.41M | 71.56M | 73.3M | 64.04M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 4.01M | 119.38M | 122.68M | 306.5M | 201M | 219.84M | 208.68M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.22M | -141.15M | -161.12M | -356.91M | -272.56M | -293.14M | -272.72M |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -16.17% | -0.14% | -1.22% | 0.24% | -0.08% | 0.07% |
| EBITDA | -8.22M | -137.23M | -150.95M | -345.84M | -256.94M | -268.58M | -255.33M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -15.69% | -0.1% | -1.29% | 0.26% | -0.05% | 0.05% |
| D&A (Non-Cash Add-back) | 1K | 3.92M | 10.17M | 11.07M | 15.63M | 24.56M | 17.39M |
| EBIT | -13.25M | -142.82M | -297.2M | -356.91M | -272.56M | -293.14M | -272.72M |
| Net Interest Income | 0 | 2.86M | 747K | 676K | 3.76M | 9.94M | 10.47M |
| Interest Income | 0 | 2.86M | 747K | 676K | 3.76M | 9.94M | 10.47M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -5.03M | 2.83M | -136.08M | 981K | 3.09M | 9.89M | 5.96M |
| Pretax Income | -13.25M | -138.32M | -297.2M | -355.93M | -269.48M | -283.25M | -266.76M |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | -7.55M | -11.9M | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 0.95% | 0.96% | 1% | 1% | 1% | 1% |
| Net Income | -13.25M | -130.78M | -285.31M | -355.93M | -269.48M | -283.25M | -266.76M |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -8.87% | -1.18% | -0.25% | 0.24% | -0.05% | 0.06% |
| Net Income (Continuing) | -13.25M | -130.78M | -285.31M | -355.93M | -269.48M | -283.25M | -266.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.07 | -0.70 | -1.63 | -2.14 | -1.43 | -1.46 | -1.16 |
| EPS Growth % | - | -8.9% | -1.33% | -0.31% | 0.33% | -0.02% | 0.21% |
| EPS (Basic) | -0.07 | -0.70 | -1.63 | -2.14 | -1.43 | -1.46 | -1.16 |
| Diluted Shares Outstanding | 187.34M | 187.34M | 187.51M | 166.43M | 188.34M | 194.54M | 230.89M |
| Basic Shares Outstanding | 187.34M | 187.34M | 187.51M | 166.43M | 188.34M | 194.54M | 230.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 32.6M | 144.26M | 384.47M | 558.1M | 444.44M | 213.51M | 160.81M |
| Cash & Short-Term Investments | 30.63M | 138.98M | 378.26M | 551M | 423.96M | 205.19M | 152.5M |
| Cash Only | 30.63M | 80.03M | 124.81M | 253.03M | 176.76M | 133.52M | 127.57M |
| Short-Term Investments | 0 | 58.95M | 253.46M | 297.97M | 247.2M | 71.68M | 24.93M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 20.47M | 8.32M | 8.31M |
| Total Non-Current Assets | 1.74M | 270.93M | 345.83M | 571.31M | 378.28M | 351.78M | 340.21M |
| Property, Plant & Equipment | 585K | 68.81M | 109.94M | 161.78M | 159.4M | 145.59M | 135.27M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M |
| Intangible Assets | 0 | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M |
| Long-Term Investments | 816K | 0 | 33.73M | 195.88M | 10.05M | 0 | 0 |
| Other Non-Current Assets | 336K | 2.3M | 2.33M | 13.82M | 9.01M | 6.37M | 5.12M |
| Total Assets | 34.33M | 415.19M | 730.3M | 1.13B | 822.72M | 565.3M | 501.02M |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 11.09% | 0.76% | 0.55% | -0.27% | -0.31% | -0.11% |
| Total Current Liabilities | 1.78M | 19.32M | 31.45M | 99.23M | 111.5M | 64.49M | 45.43M |
| Accounts Payable | 289K | 0 | 2.25M | 2.22M | 2.86M | 4.11M | 5.21M |
| Days Payables Outstanding | 105.48K | - | 80.85 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 685K | 8.09M | 14.02M | 74.63M | 76.59M | 23.46M | 300K |
| Current Ratio | 18.26x | 7.47x | 12.22x | 5.62x | 3.99x | 3.31x | 3.54x |
| Quick Ratio | 18.26x | 7.47x | 12.22x | 5.62x | 3.99x | 3.31x | 3.54x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 45.74M | 538.41M | 1.12B | 301.67M | 211.9M | 213.31M | 205.08M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 46.36M | 68.2M | 101.78M | 95.86M | 90.9M | 81.66M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 45.74M | 492.05M | 1.05B | 199.89M | 116.04M | 122.41M | 123.42M |
| Total Liabilities | 47.52M | 557.73M | 1.15B | 400.9M | 323.4M | 277.79M | 250.52M |
| Total Debt | 0 | 47.7M | 71.91M | 110.94M | 108.25M | 104.1M | 94.2M |
| Net Debt | -30.63M | -32.33M | -52.9M | -142.09M | -68.51M | -29.42M | -33.37M |
| Debt / Equity | - | - | - | 0.15x | 0.22x | 0.36x | 0.38x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -13.19M | -142.54M | -421.18M | 728.5M | 499.31M | 287.51M | 250.5M |
| Equity Growth % | - | -9.81% | -1.95% | 2.73% | -0.31% | -0.42% | -0.13% |
| Book Value per Share | -0.07 | -0.76 | -2.25 | 4.38 | 2.65 | 1.48 | 1.08 |
| Total Shareholders' Equity | -13.19M | -142.54M | -421.18M | 728.5M | 499.31M | 287.51M | 250.5M |
| Common Stock | 1K | 1K | 2K | 18K | 19K | 20K | 22K |
| Retained Earnings | -13.25M | -144.13M | -429.43M | -785.36M | -1.05B | -1.34B | -1.6B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -45.72M | 26K | 30K | -1.37M | -4.33M | -60K | 14K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.49M | -85.5M | -137.98M | -251.05M | -290.05M | -253.58M | -223.15M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -5.34% | -0.61% | -0.82% | -0.16% | 0.13% | 0.12% |
| Net Income | -13.25M | -130.78M | -285.31M | -355.93M | -269.48M | -283.25M | -266.76M |
| Depreciation & Amortization | 1K | 1.83M | 5.92M | 11.07M | 15.63M | 24.56M | 17.39M |
| Stock-Based Compensation | 118K | 1.5M | 5.83M | 22.36M | 38.34M | 35.53M | 37.68M |
| Deferred Taxes | 0 | -7.55M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -228K | 38.97M | 129.42M | 61.64M | -82.08M | -49.03M | -10.28M |
| Working Capital Changes | -308K | 10.53M | 6.16M | 9.8M | 7.54M | 18.61M | -1.19M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 289K | -421K | 1.98M | -266K | 1.06M | 1.03M | 1.38M |
| Cash from Investing | -780K | -87.86M | -252.56M | -245.8M | 210.56M | 172.01M | 17.45M |
| Capital Expenditures | -460K | -26.18M | -23.87M | -29.86M | -20.88M | -20.03M | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -320K | 59K | 0 | -4.57M | 231.44K | 192.04K | 17.45M |
| Cash from Financing | 45.72M | 223.73M | 435.69M | 631.75M | 4.91M | 31.65M | 199.75M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | -14K | 149K | 0 | 0 | 0 | 11.01M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -13.96M | -111.69M | -161.85M | -280.92M | -310.93M | -273.61M | -256.58M |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -7% | -0.45% | -0.74% | -0.11% | 0.12% | 0.06% |
| FCF per Share | -0.07 | -0.60 | -0.86 | -1.69 | -1.65 | -1.41 | -1.11 |
| FCF Conversion (FCF/Net Income) | 1.02x | 0.65x | 0.48x | 0.71x | 1.08x | 0.90x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -231.63% | -43.9% | -72% | -99.17% |
| Return on Invested Capital (ROIC) | - | - | - | -476.58% | -40.19% | -63.83% | -86.08% |
| Debt / Equity | - | - | - | 0.15x | 0.22x | 0.36x | 0.38x |
| FCF Conversion | 1.02x | 0.65x | 0.48x | 0.71x | 1.08x | 0.90x | 0.84x |
Sana Biotechnology, Inc. (SANA) grew revenue by 0.0% over the past year. Growth has been modest.
Sana Biotechnology, Inc. (SANA) reported a net loss of $234.4M for fiscal year 2024.
Sana Biotechnology, Inc. (SANA) has a return on equity (ROE) of -99.2%. Negative ROE indicates the company is unprofitable.
Sana Biotechnology, Inc. (SANA) had negative free cash flow of $158.8M in fiscal year 2024, likely due to heavy capital investments.